Welcome to our dedicated page for CYAD news (Ticker: CYAD), a resource for investors and traders seeking the latest updates and insights on CYAD stock.
Celyad Oncology SA (CYAD) is a biotechnology company headquartered in Mont‑Saint‑Guibert, Belgium, with shares admitted to trading on Euronext. Its regulatory news flow provides detailed insight into the company’s strategic focus on managing and licensing its intellectual property portfolio, including proprietary technology platforms, as well as its capital structure and major shareholdings.
News about Celyad Oncology frequently covers decisions that affect its operational profile and financial position. For example, the company has announced the discontinuation of its research and development activities and a significant reduction in its R&D workforce due to limited cash resources, stating that it will concentrate on the management and licensing of its intellectual property portfolio. Other releases describe the divestiture of its research facility’s equipment and office furniture under an asset purchase agreement, which management expects to extend the company’s cash runway.
Investors following CYAD news can also track financing transactions and ownership changes. The company has reported a private placement financing with CFIP CLYD (UK) Limited, an affiliate of Fortress Investment Group, and has issued multiple transparency notifications detailing when this shareholder has crossed voting‑rights thresholds. In addition, Celyad Oncology regularly publishes updates on the total number of shares and voting rights, including the impact of double voting rights on certain registered shares.
This news page is useful for readers who want to monitor regulatory announcements on Celyad Oncology’s strategic decisions, capital increases, asset sales, major shareholdings and voting‑rights structure. By reviewing these updates, users can follow how the company’s focus on intellectual property, its financing arrangements and its ownership profile evolve over time.
Celyad Oncology SA (Euronext & Nasdaq: CYAD) has announced participation in two upcoming virtual investor conferences in March 2021. The H.C. Wainwright Global Life Sciences Conference will occur from March 9 to March 10, while BioCapital Europe is scheduled for March 11. The company is focused on developing CAR T therapies for cancer, including both allogeneic and autologous candidates. Celyad has received funding from the Walloon Region to advance its programs and emphasizes ongoing work towards clinical trials, despite challenges posed by the COVID-19 pandemic.
Celyad Oncology SA (CYAD) announced a capital increase on January 7, 2021, issuing 262,812 new shares to Lincoln Park Capital Fund, LLC. The company's total share capital now stands at 49,427,200.33 EUR, represented by 14,132,832 shares. This transaction increases the total number of shares to 14,205,156, with diluted shares reaching 15,693,162. The press release adheres to Belgian law regarding major shareholding disclosures. Celyad focuses on developing CAR T cell therapies for cancer.
Celyad Oncology SA (CYAD) has appointed Dr. Marina Udier to its Board of Directors. Dr. Udier, a highly regarded leader in biopharmaceuticals, is expected to leverage her extensive experience in advancing the company’s CAR T therapy pipeline. CEO Filippo Petti expressed confidence in her ability to strengthen Celyad's position in the CAR T space. Dr. Udier previously served as CEO of Nouscom and held senior roles at Novartis. Celyad continues to focus on developing a robust pipeline for treating hematological malignancies and solid tumors, supported by funding from the Walloon Region in Belgium.
Celyad Oncology has entered a committed equity purchase agreement with Lincoln Park Capital for up to $40 million. Over 24 months, Celyad can direct LPC to purchase American Depositary Shares, with a maximum regular purchase of $2.5 million. LPC's purchase price will be determined by the lower of the lowest sale price on the purchase date or the average of the three lowest closing prices in the preceding ten days. The proceeds will support the company's research and development of CAR T cell therapies. Celyad ended 2020 with a treasury position of €17.2 million, sufficient to fund operations into Q3 2021.
Celyad Oncology SA (CYAD), a clinical-stage biotechnology firm, will participate in multiple conferences in January 2021. The H.C. Wainwright BioConnect Conference is scheduled for January 11-14, with a dedicated webcast available on January 11. Following this, Celyad will present at the Keystone eSymposia on January 25. The company is focused on developing CAR T therapies for cancers and has received funding from the Walloon Region of Belgium to advance its projects. Further details can be found on their official website.
Celyad Oncology SA (NASDAQ: CYAD) announced the successful dosing of the first patient in the expansion cohort of the Phase 1 alloSHRINK trial for CYAD-101, designed for refractory metastatic colorectal cancer. Preliminary data is expected in the first half of 2021. Dr. Eric Van Cutsem noted the historical challenges CAR T therapies faced in solid tumors, while Celyad's CYAD-101 aims to improve clinical outcomes using a non-gene edited, allogeneic CAR-T strategy. The trial will assess the safety and efficacy of CYAD-101 with FOLFIRI chemotherapy.
Celyad Oncology has announced significant updates regarding its CAR T candidates. The first patient has been dosed with CYAD-211 in the Phase 1 IMMUNICY-1 trial, indicating a key milestone in developing therapies for refractory multiple myeloma. Preclinical results show strong antitumor activity without Graft-versus-Host Disease. Meanwhile, the company has discontinued development of CYAD-01 due to clinical futility observed in the Phase 1 THINK trial. Encouraging initial results for CYAD-02 were reported in the ongoing CYCLE-1 trial.
Celyad Oncology has initiated the Phase 1 IMMUNICY-1 trial, dosing its first patient with CYAD-211, an innovative CAR T therapy targeting BCMA for relapsed/refractory multiple myeloma. The trial will assess safety and efficacy across various dose levels. The company secured €3.4 million in non-dilutive funding from SPW-Recherche to support CYAD-211's development. Preliminary data from the trial is anticipated in the first half of 2021, aiming to address the high unmet need for effective treatments in multiple myeloma.
Celyad Oncology SA (Euronext & Nasdaq: CYAD) announced that CEO Filippo Petti will participate in a fireside chat at the virtual JMP Securities Hematology Summit on December 16, 2020, at 10:00 a.m. ET / 4:00 p.m. CET. A live and archived webcast will be available on the company's website. Celyad Oncology focuses on developing chimeric antigen receptor T cell (CAR T) therapies for cancer, with a pipeline of allogeneic and autologous candidates targeting hematological malignancies and solid tumors. Founded in 2007, the company is based in Mont-Saint-Guibert, Belgium and New York, NY.
Celyad Oncology (CYAD) provided a business update for Q3 2020, emphasizing advancements in its clinical pipeline. Key highlights include a partnership with MSD for a Phase 1b trial of CYAD-101 combined with KEYTRUDA in metastatic colorectal cancer (mCRC) patients. The company is set to initiate the IMMUNICY-1 trial for CYAD-211 by year-end 2020, targeting relapsed/refractory multiple myeloma. As of September 30, 2020, Celyad reported a cash position of €20 million ($23.4 million) and a net cash burn of €6.7 million ($7.8 million), confirming sufficient funds through Q3 2021.